跳到主要內容

臺灣博碩士論文加值系統

(44.210.151.5) 您好!臺灣時間:2024/07/13 10:13
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:陳琬筑
研究生(外文):Wan-Chu Chen
論文名稱:犬免疫性溶血性貧血之診斷與靜脈注射人類免疫球蛋白治療之評估
論文名稱(外文):Diagnosis of Canine Immune-mediated Hemolytic Anemia and Evaluation of Intravenous Human Immunoglobulin Treatment
指導教授:蘇璧伶
指導教授(外文):Biling Su
學位類別:碩士
校院名稱:國立臺灣大學
系所名稱:獸醫學研究所
學門:獸醫學門
學類:獸醫學類
論文種類:學術論文
論文出版年:2005
畢業學年度:93
語文別:中文
論文頁數:84
中文關鍵詞:免疫性溶血性貧血靜脈注射人類免疫球蛋白
外文關鍵詞:dogimmune-mediated hemolytic anemiainravenous human immunoglobulin
相關次數:
  • 被引用被引用:0
  • 點閱點閱:2491
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:1
免疫性溶血性貧血(immune-mediated hemolytic anemia; IMHA)是犬重要免疫性疾病之一。本研究收集27隻IMHA患犬基本資料、病史、臨床症狀、血液檢查、及診斷試驗結果,藉以了解此病在台灣之現況,同時靜脈注射人類免疫球蛋白(human intravenous immunoglobulin, hIVIG)治療患犬,評估此藥之治療效果。本研究結果顯示,中年雌犬為好發族群,瑪爾濟斯犬和西施犬為本研究最多之犬種,患犬在初次就診時最常見的臨床症狀與理學檢查結果為嗜睡、厭食、黏膜蒼白,黃疸或尿色變深。就診時血液學檢查會出現貧血(100%)、白血球增多症(77.8%)、以及血小板減少症(71.4%),其中再生性貧血比例為55.6% ,非再生性貧血為44.4%。確診試驗最常見為真實自體凝集現象(77.8%),其次為陽性庫姆氏試驗(66.7%),與球狀紅血球增多症(19%)。庫姆氏試驗的結果,及出現抗體種類、數目多寡與力價高低對預後並無決定性影響,但陽性患犬治療前後力價高低變化可反應治療效果。本研究中患犬使用hIVIG來治療IMHA 6個月以上存活率達63%,無觀察到明顯副作用,且成功治療之患犬可無須再依靠免疫抑制藥物控制。對治療反應之評估,發現hIVIG治療後第7天到第14天紅血球相Hb、PCV、RBC的上升為預後良好指標,選用同廠牌不同濃度hIVIG製劑來治療並無差異,若在治療後不需要或僅需短期使用免疫抑制劑治療的患犬存活時間較長且比率較高。本研究也發現hIVIG有抑制不當輸血後快速及大量溶血的作用。而病因學、治療前血液檢查結果對預後並無影響。綜合所有之觀察,hIVIG為治療犬IMHA一種良好的選擇。
Immune-mediated hemolytic anemia (IMHA) is an important immunological disease in dogs. 27 IMHA dogs treated with human intravenous immunoglobulin (hIVIG) were included in this study. The signalments, histories, clinical findings, and blood examinations results of 27 IMHA dogs were collected to understand the present situation of canine IMHA in Taiwan, and evaluated the theraprutic effects of hIVIG. In this study, middle-age females had higher risk for IMHA than males. Maltese and Shih-Tzu were the most affected breeds. The most frequently encountered clinical signs and presentions of physical examination included lethargy, anorexia, pale mucus membrane, icterus, and pigmenturia. Blood examinations presented anemia (100%) which 55.6% were regenerative and 44.4% were non-regenerative, leukocytosis (77.8%), and thrombocytopenia (71.4%) at presenting. Diagnosis of IMHA showed 77.8% with true autoagglutination, 66.7% with positive Coombs’ test, and 19% with spherocytosis. The positive result, type of antibody and titers of Coombs’ tests could not indicate good prognosis, but the therapeutic effects were corresponded with the variation of titer. Survival rate during the 6-month observation period was 63%, and no obvious side effects were observed. The IMHA dog with good prognosis showed the increasing of Hb, PCV, and RBC during 7th day to 14th day, and without or in short time with others immunosuppressive agent after hIVIG therapy. Different concentration of same product didn’t affect therapeutic effect. Another important point was also observed, that hIVIG maybe can decrese severe hemolysis after inappropriate blood transfusion. Therefore, intravenous administration of hIVIG may be a good alternative therapy for canine IMHA.
摘要…………………………………………………… I
Abstract……………………………………………… II
目錄…………………………………………………… III
表次…………………………………………………… V
圖次…………………………………………………… VII

第一章 緒言………………………………………… 1

第二章 文獻探討…………………………………… 3
第一節 犬免疫性溶血性貧血臨床症狀與診斷… 3
第二節 犬免疫性溶血性貧血之治療…………… 8
第三節 免疫性溶血性貧血之致病機轉………… 11
第四節 hIVIG用於犬免疫性溶血性貧血之理論基礎 15
第五節 犬免疫性溶血性貧血預後之評估……… 17

第三章 材料與方法………………………………… 20
第一節 動物……………………………………… 20
第二節 免疫性溶血性貧血之診斷……………… 23
第三節 血液學及血清生化學檢查……………… 26
第四節 統計分析………………………………… 28

第四章 結果………………………………………… 29
第一節 免疫性溶血性患犬基本資料、診斷、治療及預後 29
第二節 不同濃度hIVIG治療結果之比較………… 33一、5% hIVIG…………………………… 33
二、10% hIVIG…………………………… 37
三、5% hIVIG與10% hIVIG治療前後血液學檢查值變化 38
第三節 hIVIG治療前後患犬血液學檢查值變化… 39
第四節 庫姆氏試驗與免疫性溶血性貧血之相關性 42

第五章 討論………………………………………… 65
第一節 免疫性溶血性貧血患犬基本資料及診斷 65
第二節 免疫性溶血性貧血之治療……………… 67
第三節 犬免疫性溶血性貧血預後之評估……… 70
第四節 庫姆氏試驗與免疫性溶血性貧血之相關性 74
第五節 結論……………………………………… 76

參考文獻……………………………………………… 78
沈永紹。獸醫實驗診斷學提要。華香園,台北。1997。
潘漢恩。靜脈注射人類免疫球蛋白對免疫性溶血性貧血犬隻周邊血液單核球細胞細胞素表現之影響。國立台灣大學獸醫學研究所碩士論文,台北。2001。
Barker RN, Gruffydd-Jones TJ, Stokes CR, and Elson CJ. Identification of autoantigens in canine autoimmune haemolytic anaemia. Clin Exp Immunol 85:33-40, 1991.
Barker RN, Gruffydd-Jones TJ, Stokes CR, and Elson CJ. Autoimmune hemolysis in the dog: relationship between anemia and the levels of red blood cell bound immunoglobulins and complement measured by an enzyme-linked antiglobulin test. Vet Immunol Immunopathol 34:1-20, 1992.
Björkholm M. Intravenous immunoglobulin treatment in cytopenic haematological disorders. J Intern Med 234:119-26, 1993.
Bucheler J and Cotter S. Canine immune-mediated hemolytic anemia. In: Bonagura JD, Kirk’s current veterinary therapy XII. Philadelphia: WB Saunders 152-7, 1995.
Buckley RH and Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 325:110-117, 1991.
Bussel JB. The use of intravenousγ-globulin in idiopathic thrombocytopenic purpura. Clin Immunol Immunopathol 53: S147-S155, 1989.
Bussel J, Pahwa S, Porges A, Cunningham-Rundles S, Koziner B, Morell A, and Barandun S. Correlation of in vitro antibody synthesis with the outcome of
intravenous gamma-globulin treatment of chronic idiopathic thrombocytopenic purpura. J Clin Immunol 6:50-6, 1986.

Carr AP, Panciera DL, and Kidd L. Prognostic factors for mortality and thromboembolism in canine immune-mediated hemolytic anemia: a retrospective study of 72 dogs. J Vet Intern Med 16:504-9, 2002.
Cotter SM. Autoimmune hemolytic anemia in dogs. Compend Contin Educ Pract Vet. 14:53-59, 1992.
Day MJ. Antigen specificity in canine autoimmune haemolytic anaemia. Vet Immuno Immunopathol 69:215-224, 1999.
Day MJ. Immune-mediated haematological diseases. In: Day MJ and Mackin AJ. Clinical immunology of the dog and cat. London, Manson, 69-87, 1999.
Day MJ. Immune-mediated haematological diseases and immunological assays. In: Davieson MG, Else RW, Lumsden JH. BSAVA manual of small animal clinical pathogy. London, BSAVA, 109-120, 1998.
Day MJ. Immunopathological mechanism. In: Day MJ and Mackin AJ. Clinical immunology of the dog and cat. London, Manson, 47-54, 1999.
Day MJ. Serial monitoring of clinical, haematological and immunological parameters in canine autoimmune haemolytic anaemia. J Small Anim Pract 37:523-34, 1996.
Day TK, Macintire DK, Murtaugh RJ, Mathews KA. Differing opinions on treatment of immune-mediated hemolytic anemia. J Am Vet Med Assoc 218:1414-5, 2001.
Dodds WJ. Immune-mediated disease and other causes of immune-mediated anemia: an overview. J Am Anim Hosp Assoc. 13:413-424, 1977.
Duval D, and Giger U. Vaccine-associated immune-mediated hemolytic anemia in the dog. J Vet Intern Med 10:290-5, 1996.

Farwell GE, LeGrand EK, and Cobb CC. Clinical observations on Babesia gibsoni and Babesia canis infections in dogs. J Am Anim Hosp Assoc 180:507-11, 1982.
Feldman BF, Handagama PH, and Lubberink AA. Splenectomy as adjunctive therapy for immune-mediated thrombocytopenia and hemolytic anemia in the dog. J Am Vet Med Assoc 187: 617-9, 1985.
Flores G, Cunningham-Rundles C, Newland AC, and Bussel JB. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. J. Hematol 44:237-242, 1993.
Gerber B, Steger A, Hassig M, and Glaus TM. Use of human immunoglobulin in dogs with primary immune mediated hemolytic anemia. Schweiz Arch Tierheilkd 144: 180-5, 2002.
Giger U. Regenerative anemias caused by blood loss or hemolysis. In Ettinger SF, Feldman EC, eds. Textbook of veterinary internal medicine. Philadelphia: WB Saunders.:1784-1804, 2000.
Grundy SA, and Barton C. Influence of drug treatment on survival of dogs with immune-mediated hemolytic anemia: 88 cases (1989-1999).J Am Vet Med Assoc 218:543-6, 2001.
Halliwell REW and Gorman NT. Autoimmune blood diseases. In: Halliwell REW and Gorman NT, ed. Veterinary Clinical Immunology. WB Saunders Co, Philadelphia, 308-336, 1989.
Huang HL, Lin FC, Hung KC, Wang PN, and WU D. Hemolytic anemia in native valve infective endocarditis: a case report and literature review. Jpn Circ J 63:400-3, 1999.
Jackson ML, Kruth SA: Immune-mediated hemolytic anemia and thrombocytopenia in the dog: a retrospective study of 55 cases diagnosed from 1969 through 1983 at the Western College of Veterinary Medicine. Can Vet J 26:245, 1985.
Johnson LR. Activation of the immune system and thrombosis. J Vet Intern Med 16:501-3, 2002.
Jonas LD, Thrall MA, and Weiser MG. Nonregenerative form of immune-mediated hemolytic anemia in dogs. J Am Anim Hosp Assoc 23:201-204, 1987.
Jones DR, Gruffydd-Jones TJ, Stokes CR, and Bourne FJ. Investigation into factors influencing performance of the canine antiglobulin test. Res Vet Sci 48:53-8, 1990.
Kaveri SV, Dietrich G, Hurez V, and Kazachkine MD. Intravenous immunoglobulins (IVIG) in the treatment of autoimmune diseases. Clin Exp Immunol 86:192-198, 1991.
Kellman DL and Bruyette DS. Intravenous human immunoglobulin for the treatment of immune-mediated hemolytic anemia in 13 dogs. J Vet Intern Med 11: 327-32, 1997.
Kerr R, Rawlinson PS, Cachia PG. Direct antiglobulin test negative, non spherocytic autoimmune haemolytic anaemia. Clin Lab Haematol 22:365-7, 2000.
Klag AR, Giger U, Shofer FS. Idiopathic immune-mediated hemolytic anemia in dogs: 42 cases (1986-1990). J Am Vet Med Assoc 202:783-788, 1993.
Klein MK, Dow SW, and Rosychuk RA. Pulmonary thromboembolism associated with immune-mediated hemolytic anemia in dogs: ten cases (1982-1987). J Am Vet Med Assoc 195:246-50, 1989.
Macey MG, and Newland AC. CD4 and CD8 subpopulation changed during high dose intravenous immunoglobulin treatment. Br J Haematol 76:513-520, 1995.
Malik R, Zunino P, and Hunt GB. Complete heart block associated with lupus in a dog. Aust Vet J 81:398-401, 2003.
Mason N, Duval D, Shofer FS, and Giger U. Cyclophosphamide exerts no beneficial effect over prednisone alone in the initial treatment of acute immune-mediated hemolytic anemia in dogs: a randomized controlled clinical trial. J Vet Intern Med 17:206-12, 2003.
McGuire WA, Yang HH, Bruno E, Brandt J, Briddell R, Coates TD, and Hoffman R. Treatment of antibody-mediated pre red-cell aplasia with high-dose intravenous gamma globulin. N Engl J Med 317:1004-8, 1987.
McManus PM and Craug LE. Correlation between leukocytosis and necropsy findings in dogs with immune-mediated hemolytic anemia: 34 cases (1994-1999). J Am Vet Med Assoc 218: 1308-1313, 2001.
Mellanby RJ, Holloway A, Chantrey J, Herrtage ME, and Dobson JM. Immune-mediated haemolytic anaemia associated with a sarcoma in a flat-coated retriever. J Small Anim Pract 45:21-4, 2004.
Miller E. Danazol therapy for the treatment of immune-mediated hemolytic anemia in dogs. J vet Int Med 11:130, 1997.
Miller SA, Hohenhaus AE, and Hale AS. Case-control study of blood type, breed, sex, and bacteremia in dogs with immune-mediated hemolytic anemia. J Am Vet Med Assoc 224:232-5, 2004.
Noble SJ, and Armstrong PJ. Bee sting envenomation resulting in secondary immune-mediated hemolytic anemia in two dogs. J Am Vet Med Assoc 214:1026-7, 1021, 1999.
Quigley KA, Chelack BJ, Haines DM, and Jackson ML. Application of a direct flow cytometric erythrocyte immunofluorescence assay in dogs with immune-mediated hemolytic anemia and comparison to the direct antiglobulin test. J Vet Diagn Invest 13:297-300, 2001.
Reagan WJ, Scott-Moncrieff C, Christian J, Snyder P, Kelly K, and Glickman L. Effects of human intravenous immunoglobulin on canine monocytes and lymphocytes. Am J Vet Res 59:1568-1574, 1998.
Reimer ME, Troy GC, and Warnick LD. Immune-mediated hemolytic anemia: 70 cases (1988-1996). J Am Anim Hosp Assoc 35:384-391, 1999.
Porter RE Jr and Weiser MG. Effect of immune-mediated erythrocyte agglutination on analysis of canine blood using a multichannel blood cell counting system. Vet Clin Pathol 19:45-50, 1990.
Scott-Moncrieff CJR, Reagan WJ, Glickman LT, DeNicola DB, and Harrington D. Treatment of nonregenerative anemia with human γ-globulin in dogs. J Am Vet Med Assoc 206:1895-1900, 1995.
Scott-Moncrieff CJR, Reagan WJ, Snyder PW, and Glickman LT. Intravenous administration of human immune globulin in dogs with immune-mediated hemolytic anemia. J Am Vet Med Assoc 210:1623-1627, 1997.
Scott-Moncrieff C. Immune-mediated hemolytic anemia: 70 cases (1988-1996). J Am Anim Hosp Assoc 37:11, 2001.
Scott-Moncrieff JC, Treadwell NG, McCullough SM, and Brooks MB. Hemostatic abnormalities in dogs with primary immune-mediated hemolytic anemia. J Am Anim Hosp Assoc 37:220-7, 2001.
Schiff RL. Half-life and clearance of pH 6.8 and pH 4.25 immunoglobulin G intravenous preparations in patients with primary disorders of humeral immunity. Rev Infect Dis Suppl 4:449-456, 1986.
Slappendel RJ. The diagnostic significance of the direct antiglobulin test (DAT) in anemic dogs. Vet Immunol Immunopathol 1:49-59, 1979.
Stewart AF, and Feldman BF. Immune-mediated hemolytic anemia. Part 2: clinical entity diagnosis, and treatment theory. Compend Contin Educ Pract Vet 15:372-381, 1993.
Stokol T, Blue JT, and French TW. Idiopathic pure red cell aplasia and nonregenerative immune-mediated anemia in dogs: 43 cases (1988-1999). J Am Vet Med Assoc 216:1429-1436, 2000.
Weiss D, Tvedten H. Erythrocyte disorders. In Willaed MD, Tvedten H. Small animal clinical dagnosis by laboratory methods. Philadelphia: WB Sauders :38-62, 2004.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top